masthead
Issue # 7 August/2008
In This Issue
Accepting Applications To Serve On The Board of Directors
Doctors & Science
A Provider's Story
Outreach At Ladies Run Motorcycle Rally
AIDS Walk Colorado 2008
Volunteer Update
Co-infection Retreat
Quick Links
Join Our List
Join Our Mailing List
 

Colorado  

Hepatitis C Support Groups
 
For individuals infected with hepatitis C and family members affected by hepatitis C.  Free and confidential.  New members always welcome.
 
Metro-Denver

 

Aurora - 900 Potomac, 1st Floor Staff Cafeteria ~ 1st Tues. ~ 6:30-8 p.m. ~ Consuelo (303) 367-2813

 

Englewood - 1000 Englewood Parkway ~ 4th Tues. ~ 7-8:30 p.m.  Jena` (303) 239-0336 

 

Lakewood - 11500 W. 20th ~ 2nd Tues. ~ 6:30-8 p.m.  

Betsy (303) 237-1150

 

HIV/HCV Co-Infection - 1660 S.  Albion ~ 3rd Tues.  5-6:30 p.m.  Kim (303) 862-0407

 

VA (VA Patients Only) - 1055 Clemont, Room 2E-104 ~ 2nd Wed.  12:30-1:30 p.m. 

Jena` (303) 239-0336  

 
Cap Hill- 3250 E. 6th Ave.  2nd & 4th Tues. 6:30-8 p.m.
Deidrea (720) 917-3973
 
 

Statewide

 

Boulder - 3303 N. Broadway, North Building ~ 2nd Wed. ~ 6-7:30 p.m. ~ Carrie (303) 678-6157

 

CO Springs - 825 E. Pikes Peak, 5th Floor Dining Room ~ 3rd Thurs. ~ 7-8:30 p.m. ~ David  (719) 236-1416

 

Fort Collins - 2809 E. Harmony, 3rd Floor ~ Last Wed. ~ 6:30-8 p.m. ~ Jerry (970) 214-2912

 

Grand Junction - 510 29½ Road, Room 1060 ~ 1st Wed. ~ 5:15-6:45 p.m. Rainy (970) 241-6023

 

Pueblo - Crossroads 509 East 13th Street , Last Mon. 6:30 - 8:00 p.m.

Rhonda (719) 546-6666 ext. 136 

 

 
Greetings!                               

 
Welcome to the August edition of Hep C Connection's newsletter! 
 

BB ad

Is he speaking to you or someone you know? This is one of the 6 new media campaigns Hep C Connection is launching later this summer and early fall to advertise hepatitis C and HIV/ HCV co-infection services, resources and support state-wide across Colorado. The campaigns will go out in print in various newspapers, on-line for those who enjoy receiving news electronically and radio.   
 
In this month's edition, learn about the various outreach activities we've participated in and volunteer opportunities available to sign up for! Accidental need stick injuries can still happen. Read the awakening personal story of a nurse and her experience.   
 
We want to hear from you! To comment or contribute interesting news and information about hepatitis, please send us a note at info@hepc-connection.org. The deadline for news postings is August 18th. We want to hear from you! 
 
Please share our newsletter with others by simply forwarding it to others, or by using the forwarding option at the bottom. Thank you! 
Serve On The Board of Directors For Hep C Connection - Repeat
  
Do you have an interest in giving back to your community?  If this sounds like you, Hep C Connection is accepting applications to serve on its Board of Directors.  These critical volunteer positions help us reach our mission by planning, fundraising, and overseeing programs and the financial well-being of the organization.  Board members serve for three-year terms with the possibility of being re-appointed to a second term.  They attend Board meetings every other month at a central Denver location.  In addition, our Board members are active participants in at least one committee, make donations that are personally meaningful to them, introduce new people to the organization, and raise funds through event ticket sales or corporate sponsorship requests.
 
Board members use their professional expertise to guide us in many ways.  Strategic planning, marketing, finance, and public health are just a few of the areas where we could use your expertise.  Contact Ann Eckman-McDougal by phone at 303-620-5697 or by email at
anneckman@rmpbs.org  to express your interest and receive more information about this opportunity.  Applications will be accepted through August 15, 2008, with terms beginning January 1, 2009.  Help us develop awareness and educate about hepatitis C and support those who have the virus through our many programs.

Doctors & Science
Experimental HCV Polymerase Inhibitor R1626 Demonstrates Potent Viral Suppression, but often causes neutropenia
 
By Liz Highleyman

Given the limitations of current standard therapy for chronic hepatitis C virus (HCV) using pegylated interferon plus ribavirin, researchers are studying several novel directly-targeted drugs that interfere with various steps of the HCV lifecycle.
One of these agents, Roche's R1626, is a prodrug that is metabolized in the body to R1479, an HCV NS5B polymerase inhibitor. Two recently published reports described early human clinical trials of R1626.

Pharmacokinetics and Resistance

As reported in the March 18, 2008 advance online edition of Hepatology, Stuart Roberts from the Alfred Hospital in Melbourne, Australia, and colleagues conducted a randomized, placebo-controlled, multiple ascending dose, Phase 1b study to evaluate the safety, pharmacokinetics, and antiviral activity of R1626, and to identify the maximum tolerated dose in chronic hepatitis C patients.

In this study, 47 treatment-naive participants with chronic HCV genotype 1 infection received oral R1626 at doses of 500 mg, 1500 mg, 3000 mg, or 4500 mg, or else placebo, twice daily for 14 days, with 14 days of follow-up.

Results
· Doses up to and including 3000 mg twice daily were well tolerated after 14 days of treatment.

· There was an increased frequency of adverse events at the highest (4500 mg) dose.

· Reversible mild-to-moderate hematological (blood) changes were observed with increasing doses.

· R1626 was efficiently converted to R1479 in the body, with dose-proportional pharmacokinetics observed over the entire dose range.

· The pharmacokinetics of R1479 were linear over the evaluated dose range.

· Dose-dependent and time-dependent reductions in HCV RNA were observed.

· Mean decreases in viral load after 14 days were 0.32 log10 with 500 mg, 1.2 log10 with 1500 mg, 2.6 log10 with 3000 mg, and 3.7 log10 with 4500 mg.

· No resistance to R1479 was detected after 14 days of treatment with R1626.
In conclusion, the authors wrote, these data support further studies of R1626 in combination with peginterferon alfa-2a and ribavirin for the treatment of patients with chronic HCV infection."

R1626 plus Pegylated Interferon
Results from just such a study were reported in the June 20, 2008 advance edition of the same journal. Paul Pockros of the Scripps Clinic in La Jolla, CA, and colleagues evaluated the efficacy and safety of R1626 administered for 4 weeks in combination with pegylated interferon alfa-2a (Pegasys) with or without ribavirin in previously untreated patients with HCV genotype 1.
Study participants were randomly assigned to 1 of 4 arms:
· 1500 mg R1626 twice daily + pegylated interferon (n = 21);

· 3000 mg R1626 twice daily + pegylated interferon (n = 32);

· 1500 mg R1626 twice daily + pegylated interferon + ribavirin (n = 31);

· Pegylated interferon + ribavirin with no R1626 (standard of care) (n = 20).
Results
· At 4 weeks, HCV RNA was undetectable (< 15 IU/mL) in 29% of patients in the dual 1500 mg arm, 69% in the dual 300 mg arm, and 74% in the triple 1500 mg arm, compared with only 5% in the standard of care arm.

· Mean reductions in HCV RNA from baseline to week 4 were 3.6, 4.5, 5.2, and 2.4 log10 IU/mL, respectively.

· Synergy was observed between R1626 and pegylated interferon, and between R1626 and ribavirin.

· There was no evidence of development of viral resistance mutations.

· Adverse events were mainly mild or moderate.

· 7 patients experienced 9 serious adverse events (including 1 patient with a serious event in the standard of care arm).
· The incidence of grade 4 neutropenia (low white blood cell count) was 48%, 78%, 39%, and 10%, respectively, in the 4 arms, and this was the main reason for dose reduction.
In conclusion, the study authors wrote, "A synergistic antiviral effect was observed when R1626 was combined with peginterferon alfa-2a [with or without] ribavirin."

"Dosing of R1626 was limited by neutropenia," they continued, adding that a study of different dosages of R1626 in combination with pegylated interferon and ribavirin is underway.


7/15/08

References
SK Roberts, G Cooksley, GJ Dore, and others. Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology March 18, 2008 [Epub ahead of print].
PJ Pockros, D Nelson, E Godofsky, and others. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology. June 20, 2008 [Epub ahead of print].

Article provided to you by HIVandHepatitis.com

A Provider's Story
 
Accidental needle sticks still happen, transmitting HIV, hepatitis C and other blood-borne infections to medical providers.
 
Read Karen's story, courtesy of National AIDS Treatment Advocacy Project, to learn her awakening experience.   
 
Karen Daley, RN, MPH, FAAN, thought nothing of it when she was stuck while discarding a needle after a routine blood draw at Boston's Brigham and Women's Hospital 10 years ago.
 
For the 23-year veteran of the ED, needlesticks seemed a part of the job. She had been stuck three times before with no lasting consequences. And she had no reason to think this time would be any different. In fact, she likely would have ignored the injury altogether and returned to work if a fellow nurse had not urged her to report the incident.
 
"So I went to the fast track in the ED and the nurse practitioner recommended, based on the nature of the stick - in particular, because we didn't know the source patient, that I begin prophylaxis. Because I assessed my exposure risk as low and had seen other healthcare workers come in feeling pretty sick after starting a prophylactic regime, I deferred. Unfortunately."
 
If Daley had accepted the prophylactic treatment on that July day in 1998, she might not have developed a life-threatening infection - HIV. She also acquired hepatitis C.
 
"At the time of my injury, we didn't know a lot about how effective some HIV meds were in preventing infection following exposure," Daley says. "There wasn't the literature that now indicates that 85 percent to 90 percent of these infections could possibly be prevented without post-exposure prophylaxis." Part of my message is I never thought this would happen to me, and having the opportunity to do it again, I would have taken it."
 
Since that December day 10 years ago when colleagues confirmed her diagnosis, Daley has been working to put a face to needlestick injuries in an effort to educate healthcare professionals and highlight the prevalence of such occurrences.
 
During the past 10 years, Daley has fought the infections with different combinations of drug therapies, which caused weight loss, hair loss, fatigue, nausea, rashes, and myriad other side effects. Although she no longer needs to take medication to fight the more slowly progressing hepatitis C infection, she has developed a better tolerance to her HIV medications and has returned to a relatively active lifestyle.
 
Not only has Daley, who was president of the Massachusetts Nurses Association at the time of the incident, traveled to 23 states, Asia, and Europe to spread her message, but she's embarking upon a new project - a doctoral dissertation at Boston College - to advance the body of knowledge regarding nurses' experience of these injuries. "My experience was relatively positive," she says. "I got lots of support when I was ready to be visible to my colleagues and the institution where I worked at the time of my injury. Based on what I hear from individuals as I speak around the country, I don't think that's the experience for every healthcare worker."
 
While there appears to be a vast range of experiences described by nurses who sustain needlestick injuries, the injuries themselves are commonplace. According to the Centers for Disease Control, approximately 384,325 needlestick injuries occur in U.S. hospitals each year. What's more, researchers at the International Healthcare Workers Safety Center estimate nearly 146,000 additional needlestick injuries occur annually at non-hospital sites (based on the number of needles used at the facilities) for a total of about 503,000 such injuries industry-wide each year.
 
The American Nurses Association this month announced the findings of the 2008 Study of Nurses' Views on Workplace Safety and Needlestick Injuries, an independent nationwide survey of more than 700 nurses. According to the research, nearly two-thirds (64%) of U.S. nurses say needlestick injuries and blood-borne infections remain major concerns. Further, the IHWSC estimates that HIV is transmitted to between 18 and 35 healthcare workers every year and hepatitis C to between 59 and 1,180 people annually as a result of these injuries. More staggering still is the fact that the majority of sticks are preventable. "With quality safety devices, up to 85 percent of these injuries are preventable," Daley says, adding that if retractable needles had been used at her facility and the sharps disposal box had been emptied instead of overfilled with needles, her injury could have been avoided.
 
Thanks, in part, to her efforts to spread sharps prevention awareness, the government passed the Needlestick Safety and Prevention Act of 2000, requiring healthcare facilities to use safer medical devices where feasible.
 
"I had no choice. I couldn't sit at home with this. I had to do something," Daley says. She's hoping her latest endeavor will help those like herself and the nursing profession better understand the experiences of those injured by needles, she says, adding no studies have been conducted to describe the impact and meanings of this experience. Given that nurses account for more than half of needlestick injuries, it's vital to understand how they cope with the injury and what services they require to meet their needs. "I have concerns about there being a potential gap in [meeting nurses' needs]. As we rush to provide care, we ignore the caregiver's needs and there may be some loss to the profession if nurses' needs are not met. [Giving] attention to the healthcare needs of nurses will, in the long run, allow the profession to better meet the needs of society."

 
Hep C Connection Participates With The Ladies Run
 
Hep C Connection provided hepatitis C information and education to approximately 1000 participants at this year's Ladies Run in Fairplay Colorado. It was a 2 day event July 12th  and 13th in the city of Fairplay. What's the "Ladies Run" you ask? The Ladies Run of Colorado was established in 1987. It evolved from a few lady riders sitting around a kitchen table wondering how they could get together, in one place with other motorcycle riding women, whether they packed or rode their bikes, for the camaraderie, sisterhood and love of the motorcycle tradition. Their dream was to figure out how to meet more lady riders, other than just a quick wave as they passed on the highway. A result of this dream, these ladies and others, working together, made this Run what it is today. The ride starts in various areas in and around the Denver, Colorado Springs and Ft. Collins areas and finishes in downtown Fairplay. The 2 day event offers all sorts of fun and activities including; a treasure hunt, poker run, ride-in bike show and more.
 
The ladies Run of Colorado supports several charities through the event sponsorships. Charities include Project Safeguard, Realities For Children, Hope House and the South Park Community Relief Fund. Hep C Connection, along with the many other vendors, is proud to be a strong supporter of this fun and worthy cause. To learn more about the Ladies Run of Colorado and future news
click here
 

Ladies Run

 
AIDS Walk Colorado 2008 - Join Our Team - Repeat
 
Saturday, September 6, 2008, thousands of people will come together in Denver for the 21st Annual Colorado AIDS Walk. The 5K walk/run will start at beautiful Cheesman Park and will take participants through the historic Capitol Hill area. The support received last year helped Colorado AIDS Project and the fundraising teams of more than 30 AIDS service and education providers in Colorado raise vital funds for the fight against HIV and AIDS. This year Hep C Connection is out to help again.
 
Thirty percent of HIV/AIDS patients are co-infected with Hepatitis C. The AIDS Walk plays a very important piece in the Hep C Connection mission. By joining forces with Colorado AIDS Project we are able to enjoy the benefits of a large campaign without incurring the costs of managing an event. Seventy percent of the funds we raise will go directly to Hep C Connection and the Co-Infection program.
Hep C Connection supporters can join the Hep C Connection Team to raise money and participate in the walk. Supporters who are not local or do not want to walk can also simply make donations.
 
To join the team, you can call Stewart Thomas at (720) 917-3970, or go to www.AIDSwalkcolorado.org, and select "Register" on the main page. You can choose to join a team or register individually. If you would like to join the Hep C Connection team, go to "Join a Team" and scroll to Hep C Connection on the team list. Stewart Thomas is registered as the Hep C Connection's Team Leader for this year's walk.
 
For supporters who would like to simply make a donation. Go to www.AIDSwalkcolorado.org, click on donate at the top of the main page and select team donation. From this page you can scroll to Hep C Connection and make a donation. If you are not comfortable making an online donation checks can be written to "AIDS WALK COLORADO". These checks can be mailed to Hep C Connection's office and will be delivered the day of the race.
 
Hep C Connection has many great supporters. We appreciate all the funds that we've received and hope that everyone will take the time to consider donating to this cause. We look forward to walking with those who can make it and will continue to keep everyone updated on our progress.
 

AIDS Walk photo



Volunteer Update
 
July was another busy month for the volunteer department. Several health fairs occurred including one at the U.S. Postal Service and another at Macedonia Church. We are continuing to book more and more outreach events and are excited to continue involving our volunteers with Hep C Connection's mission. While there are several health fairs in August, our next big event is AIDS Walk on September 6th. 
 
In the spirit of gearing up for this event, the Volunteer Department will be holding a Volunteer presentation on HCV/HIV Co-infection. Hep C Connection's Medical and Marketing Liaison, Stewart Thomas, will be presenting Wednesday, August 20th, at 6:00 PM. The location has not yet been finalized, dinner will be provided.  The general content covers the very basics of HIV, extensive information regarding HCV (transmission, diagnosing, disease progression and treatment), followed by issues related to co-infection. Lastly, Stewart will talk about how providers work together to address community resources. This will be a wonderful opportunity to have great discussions and to learn. We are very eager to get everyone involved, so please mark your calendars! If you are interested, RSVP to Kara Armstrong at (720) 917 3972 or by e-mail at karmstrong@hep-connection.org.
 
Finally, Hep C Connection Volunteer Department is looking for volunteers. Our National Helpline is seeking volunteer staff to answer phone calls during the week. We ask that individuals interested be willing to commit to a particular day for six months. A typical shift usually last 3 to 4 hours, and you will be providing the support and information so many need. For more information please call Kara Armstrong.
Co-Infection Retreat With The Archdiocese of Denver 
 
The Catholic Charities Archdiocese of Denver is offering a 3 day Retreat, September 5th through the 7th for those who are co-infected with Hep C and HIV. The Retreat will take place at The Jesuit House, just outside of Sedalia, 30 miles south of Denver. The Retreat promises to be cultivating and enriching through ministry. To find out more, please call Betsy at (303) 715-2042. Registration deadline is August 26th.   
Newsletter Sponsors:
Cascade Ad#4